Jouleh, Bahareh
Erdal, Marta
Eagan, Tomas Mikal
Bakke, Per
Gulsvik, Amund
Nielsen, Rune
Funding for this research was provided by:
Yara Praxair
The Norwegian Heart and Lung Patient Organisation
AstraZeneca NO
Article History
Received: 20 March 2018
Accepted: 30 November 2018
First Online: 20 December 2018
Ethics approval and consent to participate
: The Regional Committee for Medical and Health Research Ethics in Western Norway approved the study (REK Vest case number 252.04), and all participants provided written consent.
: Not applicable as no personal information is provided in the manuscript.
: BJ reports no competing interests.ME received a research grant from AstraZeneca in November 2015.TME has received fees from AstraZeneca and Boehringer Ingelheim for speaking at conferences within the last 3 years.PB reports no competing interests.AG reports no competing interests.RN reports grants from Yara Praxair, grants from The Norwegian Heart and Lung Patient Organisation, and grants from AstraZeneca during the conduct of the study; personal fees from AstraZeneca, grants from Boehringer Ingelheim, and grants from GlaxoSmithKline outside the submitted work. He is currently acting as an Associate Editor for BMC Pulmonary Medicine.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.